Posted Sep 5, 2023, 12:57 p.m.Updated Sep 5, 2023, 3:14 p.m.
Beautification operation for the generic heavyweight Sandoz. One month before its independence by split and listing on the stock exchange, scheduled for October 4, its parent company, the Swiss laboratory Novartis, details the state of health of its future ex-subsidiary in anticipation of the extraordinary general meeting of its shareholders, to validate the operation on September 15, 2023.
Novartis shareholders will be allocated one Sandoz share for every five Novartis shares. Sandoz is expected to be listed on the Swiss Stock Exchange, as well as in New York in the form of American Depositary Receipts (ADR), the negotiable security representing ownership of shares in a non-US company. The split must make Sandoz, underlines its parent company, “a world leader in generics and biosimilars” (generics of drugs when they are biological).
2023-09-05 10:57:45
#Drugs #Sandoz #good #health #approaches #independent #listing
